Good cell culture practice for stem cells & stem-cell-derived models

Altex

Volumn 34, Issue 1, 2017, Pages 95-132

  Pamies, David ^a   Bal Price, Anna ^b   Simeonov, Anton ^c   Tagle, Danilo ^c   Allen, Dave ^d   Gerhold, David ^c   Yin, Dezhong ^e   Pistollato, Francesca ^b   Inutsuka, Takashi ^f   Sullivan, Kristie ^g   Stacey, Glyn ^h   Salem, Harry ⁱ   Leist, Marcel ^j   Daneshian, Mardas ^j   Vemuri, Mohan C ^k   Mcfarland, Richard ^l   Coecke, Sandra ^b   Fitzpatrick, Suzanne C ^l   Lakshmipathy, Uma ^k   Mack, Amanda ^m   Wang, Wen Bo ^m   Yamazaki, Daiju ⁿ   Sekino, Yuko ⁿ   Kanda, Yasunari ⁿ   Smirnova, Lena ^a   Hartung, Thomas ^a,j   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Contractor Supporting NTP Interagency Center for Evaluation of Alternative Toxicological Methods ^*  (United States)

^e ATCC   (United States)

^f Pharmacological Evaluation Institute of Japan (PEIJ)   (Japan)

^g PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE   (United States)

^h NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

ⁱ EDGEWOOD CHEMICAL BIOLOGICAL CENTER   (United States)

^j UNIVERSITY OF KONSTANZ   (Germany)

^k Thermo Fisher Scientific   (United States)

^l CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^m Cellular Dynamics International   (United States)

ⁿ NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

more..

Author keywords

Alternatives to animals; Good cell culture practices; In vitro methods; Induced pluripotent stem cells

Indexed keywords

BIOTECHNOLOGY; DOCUMENTATION; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; LAW; MODEL; PRODUCT DEVELOPMENT; QUALITY CONTROL; SAFETY; STAFF; STEM CELL CULTURE; ANIMAL; ANIMAL TESTING ALTERNATIVE; CELL CULTURE TECHNIQUE; LABORATORY; ORGANIZATION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; STEM CELL;

ANIMAL TESTING ALTERNATIVES; ANIMALS; CELL CULTURE TECHNIQUES; CONGRESSES AS TOPIC; GUIDELINES AS TOPIC; HUMANS; LABORATORIES; QUALITY CONTROL; STEM CELLS;

EID: 85012027021     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1607121     Document Type: Conference Paper

References (212)

1. Adewumi, O., Aflatoonian, B., Ahrlund-Richter, L. et al. (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25, 803- 816. https://doi.org/10.1038/nbt1318.
2. Alépée, N., Bahinski, A., Daneshian, M. et al. (2014). State-of-The-Art of 3D cultures (organs-on-A-chip) in safety testing and pathophysiology. ALTEX 31, 441-477. https://doi.org/10.14573/altex1406111.
3. Amit, M., Margulets, V., Segev, H. et al. (2003). Human feeder layers for human embryonic stem cells. Biol Reprod 68, 2150- 2156. https://doi.org/10.1095/biolreprod.102.012583.
4. Andersen, M. E., Betts, K., Dragan, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools - challenges and opportunities. ALTEX 31, 364-367. https://doi.org/10.14573/altex.
5. Andrews, P. W. (2002). From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci 357, 405-417. https://doi.org/10.1098/rstb.2002.1058.
6. Andrews, P. W., Arias-Diaz, J., Auerbach, J. et al. (2009). Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev 5, 301-314. https://doi.org/10.1007/s12015-009-9085-x.
7. Andrews, P. W., Baker, D., Benvinisty, N. et al. (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med 10, 1-44. https://doi.org/10.2217/rme.14.93.
8. Anon (1980). Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure of 28 April 1977, as amended on 26 September 1980. Geneva, Switzerland: World Intellectual Property Organisation. http://www.wipo.int/treaties/en/registration/budapest/.
9. Armstrong, S. E., Mariano, J. A. and Lundin, D. J. (2010). The scope of mycoplasma contamination within the biopharmaceutical industry. Biologicals 38, 211-213. https://doi.org/10.1016/j.biologicals.2010.03.002.
10. Avior, Y., Biancotti, J. C. and Benvenisty, N. (2015). TeratoScore: Assessing the differentiation potential of human pluripotent stem cells by quantitative expression analysis of teratomas. Stem Cell Reports 4, 967-974. https://doi.org/10.1016/j.stemcr.2015.05.006.
11. Baker, D. E. C., Harrison, N. J., Maltby, E. et al. (2007). Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 25, 207-215. https://doi.org/10.1038/nbt1285.
12. Beers, J., Gulbranson, D. R., George, N. et al. (2012). Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. Nat Protoc 7, 2029-2040. https://doi.org/10.1038/nprot.2012.130.
13. Bhutani, K., Nazor, K. L., Williams, R. et al. (2016). Whole-genome mutational burden analysis of three pluripotency induction methods. Nat Commun 7, 10536. https://doi.org/10.1038/ncomms10536.
14. Bickmore, W. A. (2001). Karyotype analysis and chromosome banding. In eLS (1-7). Chichester: John Wiley & Sons Ltd. https://doi.org/10.1038/npg.els.0001160.
15. Bock, C., Kiskinis, E., Verstappen, G. et al. (2011). Reference maps of human ES and iPS cell variation enable high-Throughput characterization of pluripotent cell lines. Cell 144, 439-452. https://doi.org/10.1016/j.cell.2010.12.032.
16. Borowiak, M., Maehr, R., Chen, S. et al. (2009). Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4, 348-358. https://doi.org/10.1016/j.stem.2009.01.014.
17. Bose, B. and Sudheer, P. S. (2016). In vitro differentiation of pluripotent stem cells into functional beta islets under 2D and 3D culture conditions and in vivo preclinical validation of 3D islets. Methods Mol Biol 1341, 257-284. https://doi.org/10.1007/7651-2015-230.
18. Bouhifd, M., Hartung, T., Hogberg, H. T. et al. (2013). Review: Toxicometabolomics. J Appl Toxicol 33, 1365-1383. https://doi.org/10.1002/jat.2874.
19. Brivanlou, A. H., Gage, F. H., Jaenisch, R. et al. (2003). Setting standards for human embryonic stem cells. Science 300, 913- 916. https://doi.org/10.1126/science.1082940.
20. Bruchmuller, I., Pirkl, E., Herrmann, R. et al. (2006). Introduction of a validation concept for a PCR-based mycoplasma detection assay. Cytotherapy 8, 62-69. https://doi.org/10.1080/14653240500518413.
21. Brunner, D., Frank, J., Appl, H. et al. (2010). Serum-free cell culture: The serum-free media interactive online database. ALTEX 27, 53-62. https://doi.org/10.14573/altex.2010.1.53.
22. Budowle, B., Moretti, T. R., Niezgoda, S. J. and Brown, B. L. (1998). CODIS and PCR-based short tandem repeat loci: Law enforcement tools. In Proceedings of the Second European Symposium on Human Identification (73-88). Madison, WI: Promega Corporation. http://bit.ly/2h9xAEM.
23. Buehring, G. C., Eby, E. A. and Eby, M. J. (2004). Cell line cross-contamination: How aware are mammalian cell culturists of the problem and how to monitor it? In Vitro Cell Dev Biol Anim 40, 211-215. https://doi.org/10.1290/1543-706X(2004)40<211:CLCHAA>2.0.CO;2.
24. Burridge, P. W., Keller, G., Gold, J. D. et al. (2012). Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16-28. https://doi.org/10.1016/j.stem.2011.12.013.
25. Buta, C., David, R., Dressel, R. et al. (2013). Reconsidering pluripotency tests: Do we still need teratoma assays? Stem Cell Res Ther 11, 552-562. https://doi.org/10.1016/j.scr.2013.03.001.
26. Butler, J. M. (2006). Genetics and genomics of core short tandem repeat loci used in human identity testing. J Forensic Sci 51, 253-265. https://doi.org/10.1111/j.1556-4029.2006.00046.x.
27. Cahan, P., Li, H., Morris, S. A. et al. (2014a). CellNet: Network biology applied to stem cell engineering. Cell 158, 903-915. https://doi.org/10.1016/j.cell.2014.07.020.
28. Cahan, P., Morris, S. A., Collins, J. J. et al. (2014b). Defining cellular identity through network biology. Cell Cycle 13, 3313-3314. https://doi.org/10.4161/15384101.2014.972918.
29. Caldicott (2013). Caldicott review: Information governance in the health and care system. National Data Guardian. http://bit.ly/2h9xAEM.
30. Callaway, E. (2014). Contamination hits cell work. Nature 511, 518. https://doi.org/10.1038/511518a.
31. Chambers, S. M., Fasano, C. A., Papapetrou, E. P. et al. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27, 275-280. https://doi.org/10.1038/nbt.1529.
32. Chen, Y., Zeng, D., Ding, L. et al. (2015). Three-dimensional poly-(epsilon-caprolactone) nanofibrous scaffolds directly promote the cardiomyocyte differentiation of murine-induced pluripotent stem cells through Wnt/beta-catenin signaling. BMC Cell Biol 16, 22. https://doi.org/10.1186/s12860-015-0067-3.
33. Cheng, L. Z., Hansen, N. F., Zhao, L. et al. (2012). Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 10, 337-344. https://doi.org/10.1016/j.stem.2012.01.005.
34. Chi, K. R. (2013). Out, damned mycoplasma! Pointers for keeping your cell cultures free of mycoplasma contamination. The Scientist, December 1, 2013. http://www.the-scientist.com/?articles.view/articleNo/38381/.
35. Chin, M. H., Mason, M. J., Xie, W. et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123. https://doi.org/10.1016/j.stem.2009.06.008.
36. Coecke, S., Balls, M., Bowe, G. et al. (2005). Guidance on good cell culture practice -A report of the second ECVAM task force on good cell culture practice. Altern Lab Anim 33, 261- 287.
37. Cooper-Hannan, R., Harbell, J. W., Coecke, S. et al. (1999). The principles of good laboratory practice: Application to in vitro toxicology studies -The report and recommendations of ECVAM Workshop 37. Altern Lab Anim 27, 539-577.
38. Crook, J. M., Hei, D. and Stacey, G. (2010). The international stem cell banking initiative (ISCBI): Raising standards to bank on. In Vitro Cell Dev Biol Anim 46, 169-172. https://doi.org/10.1007/s11626-010-9301-7.
39. Dabrazhynetskaya, A., Volokhov, D. V., David, S. W. et al. (2011). Preparation of reference strains for validation and comparison of mycoplasma testing methods. J Appl Microbiol 111, 904- 914. https://doi.org/10.1111/j.1365-2672.2011.05108.x.
40. De Miguel, M. P., Fuentes-Julian, S. and Alcaina, Y. (2010). Pluripotent stem cells: Origin, maintenance and induction. Stem Cell Rev 6, 633-649. https://doi.org/10.1007/s12015-010-9170-1.
41. Dirks, W. G., MacLeod, R. A. F., Nakamura, Y. et al. (2010). Cell line cross-contamination initiative: An interactive reference database of STR profiles covering common cancer cell lines. Int J Cancer 126, 303-304. https://doi.org/10.1002/ijc.24999.
42. Doblhoff-Dier, O. and Stacey, G. (2006). Cell lines: Applications and biosafety. In D. O. Fleming and D. L. Hunt (eds.), Biological Safety - Principles and Practices (221-241). 4th edition. Washington DC: ASM Press.
43. Draper, J. S., Pigott, C., Thomson, J. A. et al. (2002). Surface antigens of human embryonic stem cells: Changes upon differentiation in culture. J Anat 200, 249-258. https://doi.org/10.1046/j.1469-7580.2002.00030.x.
44. Drexler, H. G. and Uphoff, C. C. (2002). Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39, 75-90. https://doi.org/10.1023/A:1022913015916.
45. EDQM (2015). European Directorate for the Quality of Medicines & Health Care. Annual Report 2015. Published by the Council of Europe. https://www.edqm.eu/sites/default/files/edqm-Annual-report.pdf.
46. Elliott, A. M., Elliott, K. A. H. and Kammesheidt, A. (2010). High resolution array-CGH characterization of human stem cells using a stem cell focused microarray. Mol Biotechnol 46, 234-242. https://doi.org/10.1007/s12033-010-9294-1.
47. Elliott, A. M., Elliott, K. A. and Kammesheidt, A. (2012). Array-comparative genomic hybridization characterization of human pluripotent stem cells. Methods Mol Biol 873, 261- 267. https://doi.org/10.1007/978-1-61779-794-1-17.
48. EMEA (1998). Quality of biotechnological products: Derivation and characterisation of cell substrates used for production of biotechnological/biological products. CPMP/ICH/294/95. http://bit.ly/2gsFIw3.
49. EU (1997). Directive 97/23/EC of the European Parliament and of the Council of 29 May 1997 on the approximation of the laws of the Member States concerning pressure equipment. OJ L 181, 1-55.
50. EU (2001a). Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC - Commission Declaration. OJ L 106, 1-39.
51. EU (2001b). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. 2001L0083 - EN - 30.12.2008 - 006.001 - 1. OJ L 311, 67.
52. EU (2001c) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. OJ L 121, 34.
53. EU (2006a). Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. OJ L 38, 40.
54. EU (2006b). Technical Annex 1; Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. OJ L 38, 40.
55. EU (2006c). Technical Annex 2: Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human cells and tissues. OJ L 294, 32.
56. EU (2007). Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. OJ L 324, 121.
57. EU (2009). Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms. OJ L 125, 75-97.
58. EU (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. OJ L 276, 33-79.
59. EU (2012). Commission Directive 2012/39/EU of 26 November 2012 amending Directive 2006/17/EC as regards certain technical requirements for the testing of human tissues and cells. OJ L 327, 24.
60. FDA (1997). PART 1270 - Human tissue intended for transplantation. Updated 2015.
61. FDA (1998). Guidance for industry - Guidance for human somatic cell therapy and gene therapy - March 1998. Hum Gene Ther 9, 1513-1524.
62. FDA (2001). PART 1271 - Human cells, tissues and cellular and tissue-based products. Updated 2015.
63. FDA (2003). Draft guidance for reviewers: Instructions and template for Chemistry, Manufacturing, and Control (CMC) reviewers of humansomatic cell therapy Investigational New Drug Applications (INDs). Rockville, MD: US Food and Drug Administration.
64. FDA (2007). Draft guidance for industry eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). Rockville, MD: US Food and Drug Administration.
65. FDA (2010a). Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Rockville, MD: US Food and Drug Administration.
66. FDA (2010b). CBER Annual Report. Innovative Technology Advancing Public Health.
67. FDA (2013). 21 CFR 610: General Biological Products Standards.
68. FDA (2015a). 21 CFR 210: Current Good Manufacturing Practice in manufacturing, processing, packing, or holding of drugs; General. Updated 2015.
69. FDA (2015b). 21 CFR 312 - Investigational new drug application. Updated 2015.
70. FDA (2015c). 21 CFR 600 - Biological products: General.
71. Feng, Q., Lu, S. J., Klimanskaya, I. et al. (2010). Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28, 704- 712. https://doi.org/10.1002/stem.321.
72. Ferrario, D., Brustio, R. and Hartung, T. (2014). Glossary of reference terms for alternative test methods and their validation. ALTEX 31, 319-335. https://doi.org/10.14573/altex.140331.
73. Festen, R. (2007). Understanding animal sera: Considerations for use in the production of biological therapeutics. In G. Stacey and J. Davis (eds.), Medicines from Animal Cell Culture. Chapter 4. John Wiley & Sons, Ltd. https://doi.org/10.1002/9780470723791.ch4.
74. Freedman, L. P., Gibson, M. C., Ethier, S. P. et al. (2015). Reproducibility: Changing the policies and culture of cell line authentication. Nat Methods 12, 493-497. https://doi.org/10.1038/nmeth.3403.
75. Freshney, I. (2000). Culture of Animal Cells: A Manual of Basic Technique. 4th edition (486pp). Wiley-Blackwell.
76. Frommer, W., Archer, L., Boon, B. et al. (1993). Safe biotechnology (5). Recommendations for safe work with animal and human cell-cultures concerning potential human pathogens. Appl Microbiol Biotechnol 39, 141-147. https://doi.org/10.1007/BF00228597.
77. Gao, G. Z. and Sun, T. (2013). [Be vigilant against cross contamination of tumor cells in culture]. Zhonghua Nei Ke Za Zhi 52, 715-717. https://doi.org/10.3760/cma.j.issn.0578-1426.2013.09.001.
78. Gertow, K., Przyborski, S., Loring, J. F. et al. (2007). Isolation of human embryonic stem cell-derived teratomas for the assessment of pluripotency. Curr Protoc Stem Cell Biol Chapter 1, Unit1B 4. https://doi.org/10.1002/9780470151808.sc01b04s3.
79. Gey, G. O., Coffman, W. O. and Kubiek, M. T. (1952). Tissue culture studies of proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 12, 264.
80. Gonzalez, F., Boue, S. and Belmonte, J. C. I. (2011). Methods for making induced pluripotent stem cells: Reprogramming a la carte. Nat Rev Genet 12, 231-242. https://doi.org/10.1038/nrg2937.
81. Gore, A., Li, Z., Fung, H. L. et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63-67. https://doi.org/10.1038/nature09805.
82. Gourraud, P. A., Gilson, L., Girard, M. et al. (2012). The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines. Stem Cells 30, 180-186. https://doi.org/10.1002/stem.772.
83. Gropp, M., Shilo, V., Vainer, G. et al. (2012). Standardization of the teratoma assay for analysis of pluripotency of human ES Cells and biosafety of their differentiated progeny. PLoS One 7, e45532. https://doi.org/10.1371/journal.pone.0045532.
84. Gstraunthaler, G. and Hartung, T. (1999). Bologna declaration toward good cell culture practice. Altern Lab Anim 27, 206.
85. Guenther, M. G., Frampton, G. M., Soldner, F. et al. (2010). Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 7, 249-257. https://doi.org/10.1016/j.stem.2010.06.015.
86. Hartung, T., Balls, M., Bardouille, C. et al. (2002). Good cell culture practice. ECVAM good cell culture practice task force report 1. Altern Lab Anim 30, 407-414.
87. Hartung, T., Bremer, S., Casati, S. et al. (2004). A modular approach to the ECVAM principles on test validity. Altern Lab Anim 32, 467-472.
88. Hartung, T. (2007a). Food for thought ... on cell culture. ALTEX 24, 143-152. http://www.altex.ch/resources/altex-2007-3-143-147-FFT-HartungE.pdf.
89. Hartung, T. (2007b). Food for thought ... on validation. ALTEX 24, 67-80. http://www.altex.ch/resources/altex-2007-2-67-73-HartungE.pdf.
90. Hartung, T. and Zurlo, J. (2012). Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 29, 251-260. https://doi.org/10.14573/altex.2012.3.251.
91. Hartung, T. (2013). Look back in anger - what clinical studies tell us about preclinical work. ALTEX 30, 275-291. https://doi.org/10.14573/altex.2013.3.275.
92. Hartung, T. (2014). 3D -A new dimension of in vitro research. Adv Drug Deliv Rev 69-70, vi. https://doi.org/10.1016/j.addr.2014.04.003.
93. Hay, R. J., Macy, M. L. and Chen, T. R. (1989). Mycoplasma infection of cultured cells. Nature 339, 487-488. https://doi. org/10.1038/339487a0.
94. Henderson, J. K., Draper, J. S., Baillie, H. S. et al. (2002). Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells 20, 329-337. https://doi.org/10.1634/stemcells.20-4-329.
95. Heng, B. C., Kuleshova, L. L., Bested, S. M. et al. (2005). The cryopreservation of human embryonic stem cells. Biotechnol Appl Biochem 41, 97-104. https://doi.org/10.1042/BA20040161.
96. Holm, F., Strom, S., Inzunza, J. et al. (2010). An effective serum-And xeno-free chemically defined freezing procedure for human embryonic and induced pluripotent stem cells. Hum Reprod 25, 1271-1279. https://doi.org/10.1093/humrep/deq040.
97. Hu, B. Y., Weick, J. P., Yu, J. et al. (2010). Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 107, 4335-4340. https://doi.org/10.1073/pnas.0910012107.
98. Hughes, P., Marshall, D., Reid, Y. et al. (2007). The costs of using unauthenticated, over-passaged cell lines: How much more data do we need? Biotechniques 43, 575-584. http://www.biotechniques.com/multimedia/archive/00003/BTN-A-000112598-O-3282a.pdf.
99. Hunt, C. (2007). The banking and cryopreservation of human embryonic stem cells. Transfus Med Hemother 34, 293-304. https://doi.org/DOI:10.1159/000104458.
100. Hussein, S. M., Batada, N. N., Vuoristo, S. et al. (2011). Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58-62. https://doi.org/10.1038/nature09871.
101. Illes, S., Jakab, M., Beyer, F. et al. (2014). Intrinsically active and pacemaker neurons in pluripotent stem cell-derived neuronal populations. Stem Cell Reports 2, 323-336. https://doi.org/10.1016/j.stemcr.2014.01.006.
102. Isasi, R., Andrews, P. W., Baltz, J. M. et al. (2014). Identifiability and privacy in pluripotent stem cell research. Cell Stem Cell 14, 427-430. https://doi.org/10.1016/j.stem.2014.03.014.
103. ISCBI (2009). Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev 5, 301-314. https://doi.org/10.1007/s12015-009-9085-x.
104. ISCBI (2012). Report on the ISCBI Workshop on the delivery of high quality induced pluripotent stem cells (iPSC) resources. http://www.stem-cell-forum.net/.
105. Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D. et al. (2000). Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 6, 88-95.
106. Ji, L., de Pablo, J. J. and Palecek, S. P. (2004). Cryopreservation of adherent human embryonic stem cells. Biotechnol Bioeng 88, 299-312. https://doi.org/10.1002/bit.20243.
107. Johnson, R. J., Fuggle, S. V., Mumford, L. et al. (2010). A new UK 2006 national kidney allocation scheme for deceased heart-beating donor kidneys. Transplantation 89, 387-394. https://doi.org/10.1097/TP.0b013e3181c9029d.
108. Kanda, Y., Yamazaki, D., Kurokawa, J. et al. (2016). Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system. J Pharmacol Toxicol Methods 81, 196-200. https://doi.org/10.1016/j.vascn.2016.06.007.
109. Kattman, S. J., Witty, A. D., Gagliardi, M. et al. (2011). Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228-240. https://doi.org/10.1016/j.stem.2010.12.008.
110. Kempf, H., Kropp, C., Olmer, R. et al. (2015). Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat Protoc 10, 1345-1361. https://doi.org/10.1038/nprot.2015.089.
111. Kim, K., Doi, A., Wen, B. et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290. https://doi.org/10.1038/nature09342.
112. Kleensang, A., Vantangoli, M., Odwin-DaCosta, S. et al. (2016). Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Sci Rep 6, 28994. https://doi.org/10.1038/srep28994.
113. Lai, S. S., Wei, S., Zhao, B. T. et al. (2016). Generation of knock-in pigs carrying Oct4-TdTomato reporter through CRISPR/Cas9-mediated genome engineering. PloS One 11, https://doi.org/10.1371/journal.pone.0146562.
114. Landry, J. J. M., Pyl, P. T., Rausch, T. et al. (2013). The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) 3, 1213-1224. https://doi.org/10.1534g3.113.005777.
115. Langdon, S. P. (2004). Cell culture contamination: An overview. Methods Mol Med 88, 309-317.
116. Lawrence, B., Bashiri, H. and Dehghani, H. (2010). Cross comparison of rapid mycoplasma detection platforms. Biologicals 38, 218-223. https://doi.org/10.1016/j.biologicals.2009.11.002.
117. Leist, M., Efremova, L. and Karreman, C. (2010). Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27, 309-317. https/doi.org/10.14573/altex.2010.4.309.
118. Leist, M., Hasiwa, N., Daneshian, M. et al. (2012). Validation and quality control of replacement alternatives - current status and future challenges. Toxicol Res 1, 8-22. https://doi.org/10.1039/c2tx20011b.
119. Liang, G. and Zhang, Y. (2013). Genetic and epigenetic variations in iPSCs: Potential causes and implications for application. Cell Stem Cell 13, 149-159. https://doi.org/10.1016/j.stem.2013.07.001.
120. Lincoln, C. K. and Gabridge, M. G. (1998). Cell culture contamination: Sources, consequences, prevention, and elimination. Methods Cell Biol 57, 49-65.
121. Lister, R., Pelizzola, M., Kida, Y. S. et al. (2011). Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471, 68-73. https://doi.org/10.1038/nature09798.
122. Lloyd, G., Bowen, E. T., Jones, N., et al. (1984). HFRS outbreak associated with laboratory rats in UK. Lancet 1, 1175-1176.
123. Loh, Y. H., Agarwal, S., Park, I. H. et al. (2009). Generation of induced pluripotent stem cells from human blood. Blood 113, 5476-5479. https://doi.org/10.1182/blood-2009-02-204800.
124. Loring, J., Schwartz, P. and Wesselschmidt, R. (2007). Human Stem Cell Manual. San Diego, CA: Academic Press.
125. Lund, R. J., Narva, E. and Lahesmaa, R. (2012). Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet 13, 732-744. https://doi.org/10.1038/nrg3271.
126. Mack, A. A., Kroboth, S., Rajesh, D. et al. (2011). Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. PLoS One 6, e27956. https://doi.org/10.1371/journal.pone.0027956.
127. MacLeod, R. A. F., Dirks, W. G., Matsuo, Y. et al. (1999). Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 83, 555-563.
128. Maitra, A., Arking, D. E., Shivapurkar, N. et al. (2005). Genomic alterations in cultured human embryonic stem cells. Nat Genet 37, 1099-1103. https://doi.org/10.1038/ng1631.
129. Mallon, B. S., Hamilton, R. S., Kozhich, O. A. et al. (2014). Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem Cell Res 12, 376-386. https://doi.org/10.1016/j.scr.2013.11.010.
130. Markovic, O. and Markovic, N. (1998). Cell cross-contamination in cell cultures: The silent and neglected danger. In Vitro Cell Dev Biol Anim 34, 1-8. https://doi.org/10.1007/s11626-998-0040-y.
131. Marti, M., Mulero, L., Pardo, C. et al. (2013). Characterization of pluripotent stem cells. Nat Protoc 8, 223-253. https://doi.org/10.1038/nprot.2012.154.
132. Martins-Taylor, K., Nisler, B. S., Taapken, S. M. et al. (2011). Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol 29, 488-491. https://doi.org/10.1038/nbt.1890.
133. Marx, U., Andersson, T. B., Bahinski, A. et al. (2016). Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX 33, 272-321. https://doi.org/10.14573/altex.1603161.
134. Marx, V. (2014). Cell-line authentication demystified. Nat Methods 11, 483-488. https://doi.org/10.1038/nmeth.2932.
135. Merling, R. K., Sweeney, C. L., Choi, U. et al. (2013). Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 121, E98-E107. https://doi.org/10.1182/blood-2012-03-420273.
136. Millman, J. R., Tan, J. H. and Colton, C. K. (2009). The effects of low oxygen on self-renewal and differentiation of embryonic stem cells. Curr Opin Organ Transplant 14, 694-700. https://doi.org/10.1097/MOT.0b013e3283329d53.
137. Mitalipova, M. M., Rao, R. R., Hoyer, D. M. et al. (2005). Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol 23, 19-20. https://doi.org/10.1038/nbt0105-19.
138. Muller, F. J., Schuldt, B. M., Williams, R. et al. (2011). A bioinformatic assay for pluripotency in human cells. Nat Methods 8, U315-U354. https://doi.org/10.1038/Nmeth.1580.
139. Nagaoka, M., Kobayashi, M., Kawai, C. et al. (2015). Design of a vitronectin-based recombinant protein as a defined substrate for differentiation of human pluripotent stem cells into hepatocyte-like cells. PLoS One 10, e0136350. https://doi.org/10.1371/journal.pone.0136350.
140. Nakatsuji, N., Nakajima, F. and Tokunaga, K. (2008). HLA-haplotype banking and iPS cells. Nat Biotechnol 26, 739-740. https://doi.org/10.1038/nbt0708-739.
141. Nazareth, E. J. P., Ostblom, J. E. E., Lucker, P. B. et al. (2013). High-Throughput fingerprinting of human pluripotent stem cell fate responses and lineage bias. Nat Methods 10, 1225- 1231. https://doi.org/10.1038/Nmeth.2684.
142. Nelson-Rees, W. A., Daniels, D. W. and Flandermeyer, R. R. (1981). Cross-contamination of cells in culture. Science 212, 446-452. https://doi.org/10.1126/science.6451928.
143. Nikfarjam, L. and Farzaneh, P. (2012). Prevention and detection of mycoplasma contamination in cell culture. Cell J 13, 203-212.
144. NRC - National Research Council (2013). Guide for the Care and Use of Laboratory Animals. 8th edition. Washington: The National Academies Press. https://grants.nih.gov/grants/olaw/Guide-for-The-Care-And-use-of-laboratory-Animals.pdf (accessed 23.08.2016).
145. Nubling, C. M., Baylis, S. A., Hanschmann, K. M. et al. (2015). World health organization international standard to harmonize assays for detection of mycoplasma DNA. Appl Environ Microbiol 81, 5694-5702. https://doi.org/10.1128/AEM.01150-15.
146. OECD (2005). Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD Series on Testing and Assessment 34. ENV/JM/MONO(2005)14. http://bit.ly/24oFedN.
147. Ohi, Y., Qin, H., Hong, C. et al. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 13, 541-549. https://doi.org/10.1038/ncb2239.
148. Opelz, G. and Dohler, B. (2007). Effect of human leukocyte antigen compatibility on kidney graft survival: Comparative analysis of two decades. Transplantation 84, 137-143. https://doi.org/10.1097/01.tp.0000269725.74189.b9.
149. Opelz, G. and Dohler, B. (2010). Pediatric kidney transplantation: Analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: A collaborative transplant study report. Transplantation 90, 292-297. https://doi.org/10.1097/TP.0b013e3181e46a22.
150. Orlowski, J., Boniecki, M. and Bujnicki, J. M. (2007). I-Ssp6803I: The first homing endonuclease from the PD- (D/E)XK superfamily exhibits an unusual mode of DNA recognition. Bioinformatics 23, 527-530. https://doi.org/10.1093/bioinformatics/btm007.
151. Panopoulos, A. D., Yanes, O., Ruiz, S. et al. (2012). The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 22, 168-177. https://doi.org/10.1038/cr.2011.177.
152. Paull, D., Sevilla, A., Zhou, H. et al. (2015). Automated, high-Throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods 12, 885-892. https://doi.org/10.1038/nmeth.3507.
153. Pera, M. F., Reubinoff, B. and Trounson, A. (2000). Human embryonic stem cells. J Cell Sci 113, 5-10.
154. Petersdorf, E. W. (2008). Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 20, 588-593. https://doi.org/10.1016/j.coi.2008.06.014.
155. Ph. Eur. (2012). European Pharmacopoeia. 7th edition, Chapter 2.6.7. http://bit.ly/2h9zp4A.
156. Pistollato, F., Bremer-Hoffmann, S., Healy, L. et al. (2012). Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opin Drug Metab Toxicol 8, 239-257. https://doi.org/10.1517/17425255.2012.639763.
157. Polouliakh, N. (2013). Reprogramming resistant genes: In-depth comparison of gene expressions among iPS, ES, and somatic cells. Front Physiol 4, 7. https://doi.org/10.3389/fphys.2013.00007.
158. Raab, S., Klingenstein, M., Liebau, S. et al. (2014). A comparative view on human somatic cell sources for iPSC generation. Stem Cells Int 2014, 768391. https://doi.org/10.1155/2014/768391.
159. Ramirez, T., Daneshian, M., Kamp, H. et al. (2013). Metabolomics in toxicology and preclinical research. ALTEX 30, 209-225. https://doi.org/10.14573/altex.2013.2.209.
160. Richards, M., Tan, S. P., Tan, J. H. et al. (2004). The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 22, 51-64. https://doi.org/10.1634/stemcells.22-1-51.
161. Riedel, M., Jou, C. J., Lai, S. et al. (2014). Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells. Stem Cell Reports 3, 131-141. https://doi.org/10.1016/j.stemcr.2014.04.017.
162. Rizzino, A. (2010). Stimulating progress in regenerative medicine: Improving the cloning and recovery of cryopreserved human pluripotent stem cells with ROCK inhibitors. Regen Med 5, 799-807. https://doi.org/10.2217/rme.10.45.
163. Robinson, L. B. and Wichelhausen, R. H. (1956). Contamination of human cell cultures by pleuropneumonialike organisms. Science 124, 1147-1148.
164. Rojas, A., Gonzalez, I. and Figueroa, H. (2008). Cell line cross-contamination in biomedical research: A call to prevent unawareness. Acta Pharmacol Sin 29, 877-880. https://doi.org/10.1111/j.1745-7254.2008.00809.x.
165. Rottem, S. and Barile, M. F. (1993). Beware of mycoplasmas. Trends Biotechnol 11, 143-151. https://doi.org/10.1016/0167-7799(93)90089-R.
166. Ruan, J. L., Tulloch, N. L., Saiget, M. et al. (2015). Mechanical stress promotes maturation of human myocardium from pluripotent stem cell-derived progenitors. Stem Cells 33, 2148-2157. https://doi.org/10.1002/stem.2036.
167. Russell, W. M. S. and Burch, R. L. (1959). The Principles of Humane Experimental Technique (238pp). London, UK: Methuen.
168. Sander, J. D. and Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32, 347-355. https://doi.org/10.1038/nbt.2842.
169. Sathananthan, A. H. and Trounson, A. (2005). Human embryonic stem cells and their spontaneous differentiation. Ital J Anat Embryol 110, 151-157.
170. Seltmann, S., Lekschas, F., Muller, R. et al. (2016). hPSCreg -The human pluripotent stem cell registry. Nucleic Acids Res 44, D757-D763. https://doi.org/10.1093/nar/gkv963.
171. Serwold, T., Hochedlinger, K., Inlay, M. A. et al. (2007). Early TCR expression and aberrant T cell development in mice with endogenous prerearranged T cell receptor genes. J Immunol 179, 928-938. https://doi.org/10.4049/jimmunol.179.2.928.
172. Shi, Y., Do, J. T., Desponts, C. et al. (2008). A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2, 525-528. https://doi.org/10.1016/j.stem.2008.05.011.
173. Silva, M. M., Rodrigues, A. F., Correia, C. et al. (2015). Robust expansion of human pluripotent stem cells: Integration of bioprocess design with transcriptomic and metabolomic characterization. Stem Cells Transl Med 4, 731-742. https://doi.org/10.5966/sctm.2014-0270.
174. Singh, U., Quintanilla, R. H., Grecian, S. et al. (2012). Novel live alkaline phosphatase substrate for identification of pluripotent stem cells. Stem Cell Rev 8, 1021-1029. https://doi.org/10.1007/s12015-012-9359-6.
175. Sohn, Y. D., Han, J. W. and Yoon, Y. S. (2012). Generation of induced pluripotent stem cells from somatic cells. Prog Mol Biol Transl Sci 111, 1-26. https://doi.org/10.1016/B978-0-12-398459-3.00001-0.
176. Sperger, J. M., Chen, X., Draper, J. S. et al. (2003). Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Nat Acad Sci U S A 100, 13350-13355. https://doi.org/10.1073/pnas.2235735100.
177. Stacey, G. N. (2000). Cell contamination leads to inaccurate data: We must take action now. Nature 403, 356-356. https://doi.org/10.1038/35000394.
178. Stacey, G. and Hartung, T. (2007). The use of human tissues in drug discovery: Scientific, ethical, legal, and regulatory environments. In U. Marx and V. Sandig (eds.), Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. Wiley-Blackwell.
179. Stacey, G. N., Crook, J. M., Hei, D. et al. (2013). Banking human induced pluripotent stem cells: Lessons learned from embryonic stem cells? Cell Stem Cell 13, 385-388. https://doi.org/10.1016/j.stem.2013.09.007.
180. Stacey, G., Coecke, S., Price, A. et al. (2016). Ensuring the quality of stem cell-derived in vitro models for toxicity testing. In C. Eskes and M. Whelan (eds.), Validation of Alternative Methods for Toxicity Testing (259-297). Advances in Experimental Medicine and Biology 856. Springer. https://doi.org/10.1007/978-3-319-33826-2.
181. Stacey, G., Healy, H., Mann, J. et al. (2017). Fundamental points to consider in the cryopreservation and shipment of cells for human application. In C. Connon (ed.), Bioprocessing for Cell-based Therapies. Wiley-Blackwell.
182. Stadtfeld, M., Nagaya, M., Utikal, J. et al. (2008). Induced pluripotent stem cells generated without viral integration. Science 322, 945-949. https://doi.org/10.1126/science.1162494.
183. Steinemann, D., Gohring, G. and Schlegelberger, B. (2013). Genetic instability of modified stem cells -A first step towards malignant transformation? Am J Stem Cells 2, 39-51.
184. Suter-Dick, L., Alves, P., Blaauboer, B. et al. (2015). Stem cell-derived systems in toxicology assessment. Stem Cells Dev 24, 1284-1296. https://doi.org/doi:10.1089/scd.2014.0540.
185. Tan, H. K., Toh, C. X. D., Ma, D. R. et al. (2014). Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. Stem Cells Transl Med 3, 586-598. https://doi.org/10.5966/sctm.2013-0195.
186. Tao, Y. W., Shih, J., Sinacore, M. et al. (2011). Development and Implementation of a perfusion-based high cell density cell banking process. Biotechnol Prog 27, 824-829. https://doi.org/10.1002/btpr.599.
187. Taylor, C. J., Peacock, S., Chaudhry, A. N. et al. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 11, 147-152. https://doi.org/10.1016/j.stem.2012.07.014.
188. Thompson, R., Zoppis, S. and McCord, B. (2012). An overview of DNA typing methods for human identification: Past, present, and future. Methods Mol Biol 830, 3-16. https://doi.org/10.1007/978-1-61779-461-2-1.
189. Timenetsky, J., Santos, L. M., Buzinhani, M. et al. (2006). Detection of multiple mycoplasma infection in cell cultures by PCR. Braz J Med Biol Res 39, 907-914.
190. Trounson, A. (2006). The production and directed differentiation of human embryonic stem cells. Endocr Rev 27, 208-219. https://doi.org/10.1210/er.2005-0016.
191. Tsai, Y., Cutts, J., Kimura, A. et al. (2015). A chemically defined substrate for the expansion and neuronal differentiation of human pluripotent stem cell-derived neural progenitor cells. Stem Cell Res 15, 75-87. https://doi.org/10.1016/j.scr.2015.05.002.
192. UK (2004). Human Tissue Act 2004 (c 30). 15 November 2004. http://www.legislation.gov.uk/ukpga/2004/30/pdfs/ukpga-20040030-en.pdf (accessed 23.08.2016).
193. van der Valk, J., Mellor, D., Brands, R. et al. (2004). The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18, 1-12. https://doi.org/10.1016/j.tiv.2003.08.009.
194. Vaskova, E. A., Stekleneva, A. E., Medvedev, S. P. et al. (2013). "Epigenetic memory" phenomenon in induced pluripotent stem cells. Acta Naturae 5, 15-21.
195. Ware, C. B., Nelson, A. M. and Blau, C. A. (2005). Controlled-rate freezing of human ES cells. Biotechniques 38, 879-880, 882-873.
196. Weber, D. J. (2006). Manufacturing considerations for clinical uses of therapies derived from stem cells. Methods Enzymol 420, 410-430. https://doi.org/10.1016/S0076-6879(06)20020-X.
197. Whitesides, G. M. (2006). The origins and the future of microfluidics. Nature 442, 368-373. https://doi.org/10.1038/nature05058.
198. WHO - World Health Organisation (2013). Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterisation of cell banks. WHO Expert Committee on Biological Standardization. Sixty-first report. WHO Technical Report Series, No 978, Annex 3. http://www.who.int/biologicals/vaccines/TRS-978-Annex-3.pdf.
199. Woltjen, K., Michael, I. P., Mohseni, P. et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770. https://doi.org/10.1038/nature07863.
200. Wu, J., Hunt, S. D., Xue, H. et al. (2016). Generation and validation of PAX7 reporter lines from human iPS cells using CRISPR/Cas9 technology. Stem Cell Res 16, 220-228. https://doi.org/10.1016/j.scr.2016.01.003.
201. Xu, H. L., Baroukh, C., Dannenfelser, R. et al. (2013). ESCAPE: Database for integrating high-content published data collected from human and mouse embryonic stem cells. Database (Oxford) 2013, bat045. https://doi.org/10.1093/database/bat045.
202. Xue, H., Wu, J., Li, S. et al. (2016). Genetic modification in human pluripotent stem cells by homologous recombination and CRISPR/Cas9 System. Methods Mol Biol 1307, 173-190. https://doi.org/10.1007/7651-2014-73.
203. Ye, L., Muench, M. O., Fusaki, N. et al. (2013). Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by sendai viral vectors. Stem Cells Transl Med 2, 558-566. https://doi.org/10.5966/sctm.2013-0006.
204. Yoshioka, N., Gros, E., Li, H. R. et al. (2013). Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 13, 246-254. https://doi.org/10.1016/j.stem.2013.06.001.
205. Young, L., Sung, J., Stacey, G. et al. (2010). Detection of mycoplasma in cell cultures. Nat Protoc 5, 929-934. https://doi.org/10.1038/nprot.2010.43.
206. Yu, J., Vodyanik, M. A., Smuga-Otto, K. et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920. https://doi.org/10.1126/science.1151526.
207. Yu, J., Hu, K., Smuga-Otto, K. et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801. https://doi.org/10.1126/science.1172482.
208. Yu, M., Selvaraj, S. K., Liang-Chu, M. M. Y. et al. (2015). A resource for cell line authentication, annotation and quality control. Nature 520, 307. https://doi.org/10.1038/nature14397.
209. Zhang, P. W., Haidet-Phillips, A. M., Pham, J. T. et al. (2016). Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology. Glia 64, 63-75. https://doi.org/10.1002/glia.22903.
210. Zhao, B., Yang, D., Jiang, J. et al. (2014). Genome-wide mapping of miRNAs expressed in embryonic stem cells and pluripotent stem cells generated by different reprogramming strategies. BMC Genomics 15, 488. https://doi.org/10.1186/1471-2164-15-488.
211. Zhao, L., Bonocora, R. P., Shub, D. A. et al. (2007). The restriction fold turns to the dark side: A bacterial homing endonuclease with a PD-(D/E)-XK motif. EMBO J 26, 2432- 2442. https://doi.org/10.1038/sj.emboj.7601672.
212. Zimmermann, A., Preynat-Seauve, O., Tiercy, J. M. et al. (2012). Haplotype-based banking of human pluripotent stem cells for transplantation: Potential and limitations. Stem Cells Dev 21, 2364-2373. https://doi.org/10.1089/scd.2012.0088.